Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN M FRISHBERG

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1952346348
CMS profile
361484
Location
CARLSBAD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$333,778.04

622 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 13; records 101–150 of 622 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN M FRISHBERG

NPI 1952346348 · CMS profile ID 361484

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CARLSBAD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 13; records 101–150 of 622 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952346348?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN M FRISHBERG, NPI 1952346348, CMS profile ID 361484. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 13; records 101–150 of 622 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952346348?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BENJAMIN M FRISHBERG, NPI 1952346348, CMS profile ID 361484. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 13; records 101–150 of 622 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952346348?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BENJAMIN M FRISHBERG, NPI 1952346348, CMS profile ID 361484, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 13; records 101–150 of 622 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1952346348?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

622 matching records · $333,778.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 622 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 622.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $17.3811/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991499 CMS
Novartis Pharmaceuticals Corporation $228.9811/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991505 CMS
Biogen, Inc. $145.3111/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660603019 CMS
Biogen, Inc. $23.6711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660603061 CMS
Sunovion Pharmaceuticals Inc. $16.6511/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687942117 CMS
CSL Behring $15.7511/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683833121 CMS
Merz North America, Inc. $17.1411/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689355149 CMS
Novartis Pharmaceuticals Corporation $9.9011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991327 CMS
Genentech USA, Inc. $218.4411/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681358699 CMS
Genentech USA, Inc. $235.1311/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681324197 CMS
Genentech USA, Inc. $17.0211/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681332637 CMS
Genentech USA, Inc. $104.4411/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681351165 CMS
Genentech USA, Inc. $381.4011/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681356919 CMS
Genentech USA, Inc. $115.6911/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681359445 CMS
Genentech USA, Inc. $4,500.0011/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681382109 CMS
Biogen, Inc. $3.4910/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660603059 CMS
GENZYME CORPORATION $12.5810/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694182949 CMS
EMD Serono, Inc. $121.0510/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702953599 CMS
EMD Serono, Inc. $33.1510/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702962639 CMS
EMD Serono, Inc. $20.1810/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702972877 CMS
EMD Serono, Inc. $9.3410/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703010217 CMS
EMD Serono, Inc. $169.7610/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702952211 CMS
EMD Serono, Inc. $70.4810/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702957913 CMS
EMD Serono, Inc. $2.6510/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703021949 CMS
Novartis Pharmaceuticals Corporation $2,485.0010/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991435 CMS
Novartis Pharmaceuticals Corporation $371.6410/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991441 CMS
Novartis Pharmaceuticals Corporation $3,976.0010/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991445 CMS
Novartis Pharmaceuticals Corporation $14.6610/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991451 CMS
Novartis Pharmaceuticals Corporation $202.5610/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991455 CMS
Novartis Pharmaceuticals Corporation $282.0010/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991459 CMS
Lilly USA, LLC $900.0010/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657704739 CMS
Novartis Pharmaceuticals Corporation $8.1610/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991325 CMS
Novartis Pharmaceuticals Corporation $13.2410/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991513 CMS
Lilly USA, LLC $5.7610/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657715149 CMS
Novartis Pharmaceuticals Corporation $4.0010/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991509 CMS
Neurocrine Biosciences, Inc. $11.2410/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693127897 CMS
Sunovion Pharmaceuticals Inc. $19.2810/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687942115 CMS
Allergan Inc. $115.5410/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670373285 CMS
Genentech USA, Inc. $4.9310/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681329865 CMS
Novartis Pharmaceuticals Corporation $9.5610/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991549 CMS
Alexion Pharmaceuticals, Inc. $3.3510/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695526471 CMS
Alexion Pharmaceuticals, Inc. $114.8410/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695526473 CMS
Alexion Pharmaceuticals, Inc. $3,565.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695526545 CMS
EMD Serono, Inc. $3,870.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702946121 CMS
Novartis Pharmaceuticals Corporation $35.3010/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991465 CMS
Novartis Pharmaceuticals Corporation $2,485.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991469 CMS
Novartis Pharmaceuticals Corporation $117.2710/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659991475 CMS
Celgene Corporation $133.2810/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672944723 CMS
Biogen, Inc. $23.1510/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660603017 CMS
Biogen, Inc. $64.9610/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660603015 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $333,778.04 622
PY2020 $180,444.89 280
PY2021 $217,689.25 379
PY2022 $218,348.02 387
PY2023 $130,918.65 264
PY2024 $95,268.78 266
PY2025 $43,449.76 199

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $730,612.14 71
PY2024 Recipient $250.00 1
PY2024 Principal investigator $1,218,516.68 40
PY2023 Recipient $453.00 2
PY2023 Principal investigator $1,095,856.38 40
PY2022 Recipient $782.00 2
PY2022 Principal investigator $1,408,636.08 29
PY2021 Principal investigator $1,189,278.22 85
PY2020 Recipient $3,882.80 4
PY2020 Principal investigator $533,530.24 64
PY2019 Principal investigator $754,851.69 97

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,545.00 12/31/2025 Non-covered Recipient Entity
NORTH COUNTY NEUROLOGY ASSOCIATES
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202535135
Principal investigator 1 Ipsen Innovation $3,420.55 12/24/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301973
Principal investigator 1 Ipsen Innovation $5,000.00 12/01/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301967
Principal investigator 1 Ipsen Innovation $300.00 12/01/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301969
Principal investigator 1 Ipsen Innovation $983.83 12/01/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301971
Principal investigator 1 Ipsen Innovation $300.00 12/01/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301975
Principal investigator 1 Ipsen Innovation $300.00 12/01/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301977
Principal investigator 1 GENZYME CORPORATION $100.00 11/04/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226132223
Principal investigator 1 GENZYME CORPORATION $565.00 11/04/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226132238
Principal investigator 1 Ipsen Innovation $2,834.75 10/22/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301951
Principal investigator 1 Ipsen Innovation $983.83 10/22/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301953
Principal investigator 1 Ipsen Innovation $4,165.85 10/22/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301955
Principal investigator 1 Ipsen Innovation $4,165.85 10/22/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301957
Principal investigator 1 Ipsen Innovation $675.00 10/17/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301959
Principal investigator 1 Ipsen Innovation $983.83 09/29/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301943
Principal investigator 1 Ipsen Innovation $675.00 09/17/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301939
Principal investigator 1 Ipsen Innovation $300.00 09/12/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301947
Principal investigator 1 GENZYME CORPORATION $3,150.00 09/08/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226132130
Principal investigator 1 GENZYME CORPORATION $200.00 09/08/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226132134
Principal investigator 1 Ipsen Innovation $916.40 09/08/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301941
Principal investigator 1 Ipsen Innovation $4,318.10 09/08/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301945
Principal investigator 1 GENZYME CORPORATION $220.00 09/03/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226132164
Principal investigator 1 GENZYME CORPORATION $420.00 09/03/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226132174
Principal investigator 1 GENZYME CORPORATION $60.00 09/03/2025 Non-covered Recipient Entity
Profound Research Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226132192
Principal investigator 1 Ipsen Innovation $126.00 08/19/2025 Non-covered Recipient Entity
The Neurology Center Of Southern California
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287364
Principal investigator 1 Ipsen Innovation $1,240.00 08/02/2025 Non-covered Recipient Entity
The Neurology Center Of Southern California
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287366
Principal investigator 1 Ipsen Innovation $845.00 08/02/2025 Non-covered Recipient Entity
The Neurology Center Of Southern California
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287368
Principal investigator 1 Ipsen Innovation $500.00 07/30/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301899
Principal investigator 1 Ipsen Innovation $1,200.00 07/30/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301901
Principal investigator 1 Ipsen Innovation $600.00 07/30/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301917
Principal investigator 1 Ipsen Innovation $3,234.95 07/28/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301893
Principal investigator 1 Ipsen Innovation $72.50 07/28/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301923
Principal investigator 1 Ipsen Innovation $3,103.00 07/28/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301929
Principal investigator 1 Ipsen Innovation $543.83 07/28/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301931
Principal investigator 1 Ipsen Innovation $362.50 07/14/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301925
Principal investigator 1 Ipsen Innovation $72.50 07/14/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301933
Principal investigator 1 Ipsen Innovation $145.00 07/14/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301935
Principal investigator 1 Ipsen Innovation $4,165.85 07/11/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301895
Principal investigator 1 Ipsen Innovation $165.30 07/11/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301897
Principal investigator 1 Ipsen Innovation $983.83 07/11/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301927
Principal investigator 1 Ipsen Innovation $600.00 07/07/2025 Non-covered Recipient Entity
Profound Research Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301903
Principal investigator 1 Ipsen Innovation $3,390.10 06/27/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287164
Principal investigator 1 Ipsen Innovation $2,821.70 06/27/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287166
Principal investigator 1 Ipsen Innovation $150.00 06/26/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287170
Principal investigator 1 Ipsen Innovation $3,661.25 06/18/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287168
Principal investigator 1 Ipsen Innovation $300.00 05/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287162
Principal investigator 1 Ipsen Innovation $300.00 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287150
Principal investigator 1 Ipsen Innovation $2,676.70 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287156
Principal investigator 1 Ipsen Innovation $983.83 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287158
Principal investigator 1 Ipsen Innovation $3,350.95 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287160
Principal investigator 1 Ipsen Innovation $2,925.00 04/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287154
Principal investigator 1 GENZYME CORPORATION $400.00 04/14/2025 Non-covered Recipient Entity
Profound Research Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226131932
Principal investigator 1 Ipsen Innovation $1,000.00 04/01/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287152
Principal investigator 1 Ipsen Innovation $1,980.00 03/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287140
Principal investigator 1 Ipsen Innovation $300.00 03/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287142
Principal investigator 1 Ipsen Innovation $945.00 03/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287146
Principal investigator 1 Eli Lilly and Company $2,540.00 03/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF HOMESTEAD INC
MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS No dispute reported 06/30/2026 1187877545
Principal investigator 1 GENZYME CORPORATION $20,763.40 03/17/2025 Non-covered Recipient Entity
Profound Research Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226131848
Principal investigator 1 Ipsen Innovation $4,310.85 03/17/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287144
Principal investigator 1 Ipsen Innovation $4,460.85 03/13/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287148
Principal investigator 1 Amgen Inc. $64,225.50 03/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246646816
Principal investigator 1 GENZYME CORPORATION $140.00 03/10/2025 Non-covered Recipient Entity
Profound Research Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226131839
Principal investigator 1 Eli Lilly and Company $4,138.64 01/31/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890046
Principal investigator 1 Eli Lilly and Company $207.00 01/27/2025 Non-covered Recipient Entity
NORTH COUNTY NEUROLOGY ASSOCIATES
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887032
Principal investigator 1 GENZYME CORPORATION $800.00 01/27/2025 Non-covered Recipient Entity
Profound Research Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226131844
Principal investigator 1 Eli Lilly and Company $2,001.20 01/24/2025 Non-covered Recipient Entity
NORTH COUNTY NEUROLOGY ASSOCIATES
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886422
Principal investigator 1 Eli Lilly and Company $156,059.00 01/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187888188
Principal investigator 1 Eli Lilly and Company $54,236.00 01/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187890044
Principal investigator 1 GENZYME CORPORATION $8,199.80 01/13/2025 Non-covered Recipient Entity
Profound Research Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226131901
Principal investigator 1 Eli Lilly and Company $357.72 01/09/2025 Non-covered Recipient Entity
NORTH COUNTY NEUROLOGY ASSOCIATES
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885072
Principal investigator 1 Eli Lilly and Company $328,444.40 01/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187889584